Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Malignancies

Interventions

DRUG: Parsaclisib
DRUG: parsaclisib + itacitinib
DRUG: parsaclisib + ruxolitinib
DRUG: parsaclisib + ibrutinib

Sponsor

Incyte Corporation